Table of contents


Top

Editorial

Risky business p345

doi:10.1038/nm0409-345

A recent US Supreme Court ruling places responsibility for the wording of drug labels on pharmaceutical companies. But the task of improving the communication of drug risks does not rest with the pharmaceutical industry alone.


Top

News

A stem cell ban is lifted, but some states see a heavy backlash p347

Kirsten Dorans

doi:10.1038/nm0409-347


Five big ideas for nanotechnology p348

Jon Evans

doi:10.1038/nm0409-348


Biosafety bungle leads to bird flu contamination p349

Cassandra Willyard

doi:10.1038/nm0409-349a


Blueprint for autism research put forward p349

Virginia Hughes

doi:10.1038/nm0409-349b


US stimulus bill challenges biomedicine to deliver p350

Kirsten Dorans

doi:10.1038/nm0409-350a


New cancer research centers open in UK p350

Nayanah Siva

doi:10.1038/nm0409-350b


Dutch seizure of drugs sparks outcry p350

Nayanah Siva

doi:10.1038/nm0409-350c


A vaccine based on conserved regions could prove radical p351

Kirsten Dorans

doi:10.1038/nm0409-351a


Broad-acting HPV vaccines explored to fight cancer p351

Kirsten Dorans

doi:10.1038/nm0409-351b


News in brief pp352 - 353

doi:10.1038/nm0409-352


Straight talk with ... Agnès Saint Raymond pp354 - 355

Genevive Bjorn

doi:10.1038/nm0409-354

Agnès Saint Raymond has long advocated for children's health and worked with members of the European Parliament to draft and pass new legislation in 2006 to promote drug development in this area. She spoke with Genevive Bjorn about the future of medicines designed for youngsters.


Top

News Feature

The curious case of clioquinol pp356 - 359

Lauren Cahoon

doi:10.1038/nm0409-356

An indigestion drug blamed for a debilitating illness that affected thousands of people in the 1950s has been resurrected as a potential treatment for Alzheimer's disease. But not everyone is cheering for the drug, clioquinol, to make a comeback. Lauren Cahoon reports.


Top

Book Review

A new progressive era? p361

Scott H Podolsky reviews Our Daily Meds: How the Pharmaceutical Companies Transformed Themselves into Slick Marketing Machines and Hooked the Nation on Prescription Drugs by Melody Petersen

doi:10.1038/nm0409-361


Top

News and Views

Choosing between GVHD and delayed engraftment pp363 - 364

Paul J Martin

doi:10.1038/nm0409-363

Growth factors used to accelerate engraftment after hematopoietic cell transplantation can increase the severity of graft-versus-host disease. Experiments with mice examine how irradiation, used to prepare recipients for transplants, contributes to this problem (pages 436–441).

See also: Letter by Morris et al.


Neutrophil sandwiches injure the microcirculation pp364 - 366

Mark R Looney & Michael A Matthay

doi:10.1038/nm0409-364

Experiments in two mouse models of thromboinflammatory disease show how neutrophils stick to red blood cells and platelets—leading to reduced blood flow and damage to the microcirculation. Polarized expression of alphaMbeta2 integrins on neutrophils helps set the process in motion (pages 384–391).

See also: Article by Hidalgo et al.


Dust mites' dirty dealings in the lung pp366 - 367

Clare M Lloyd

doi:10.1038/nm0409-366

Toll-like receptors on lung epithelia recognize allergens and help provoke asthma. The findings put new emphasis on innate immunity as a driver of allergic responses (pages 410–416).

See also: Article by Hammad et al.


Neuropeptide beckons cells that heal pp367 - 369

Pamela Gehron Robey

doi:10.1038/nm0409-367

Experiments in rodents identify a factor that causes the release of multipotent cells into the circulation after injury. These cells contribute to tissue repair (pages 425–435).

See also: Article by Hong et al.


Top

Community Corner

Bone marrow transplant muffles HIV p371

doi:10.1038/nm0409-371


Top

Between Bedside and Bench

Getting away from glucose: stop sugarcoating diabetes pp372 - 373

Babak Razani & Clay F Semenkovich

doi:10.1038/nm0409-372

Type 2 diabetes is often viewed as a disorder of glucose metabolism. But many factors come into play in this condition, with obesity a prime risk factor and cardiovascular disease a major result. In Bedside to Bench, Babak Razani and Clay Semenkovich examine the linkages between diabetes and cardiovascular disease. They call for new research approaches in the wake of clinical trials showing that lowering glucose levels does not decrease cardiovascular events in people with type 2 diabetes. In Bench to Bedside, Steven Shoelson and Allison Goldfine examine how type 2 diabetes and other disorders can stem from obesity—and its effect on inflammation. These authors take a look at two recent studies showing how obesity perturbs inflammatory gene networks.


Getting away from glucose: fanning the flames of obesity-induced inflammation pp373 - 374

Steven E Shoelson & Allison B Goldfine

doi:10.1038/nm0409-373


Top

Research Highlights

Research Highlights p375

doi:10.1038/nm0409-375


Top

Brief Communications

Amyloid precursor protein secretases as therapeutic targets for traumatic brain injury pp377 - 379

David J Loane, Ana Pocivavsek, Charbel E-H Moussa, Rachel Thompson, Yasuji Matsuoka, Alan I Faden, G William Rebeck & Mark P Burns

doi:10.1038/nm.1940

The neurotoxic Abeta peptide is produced after traumatic brain injury. Mark P. Burns and his colleagues show that inhibiting the enzymes involved in Abeta production can block the neuron death and neurological dysfunction that occurs after traumatic brain injury.


Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans pp380 - 383

Hiroshi Watanabe, Nagesh Chopra, Derek Laver, Hyun Seok Hwang, Sean S Davies, Daniel E Roach, Henry J Duff, Dan M Roden, Arthur A M Wilde & Björn C Knollmann

doi:10.1038/nm.1942

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmia syndrome that is often difficult to treat. Hiroshi Watanabe and coworkers now show that flecainide, an approved drug known to inhibit sodium channels, is able to target the underlying cause of CPVT by inhibiting calcium release through the ryanodine receptor. Flecainide prevented arrhythmia in a mouse model of CPVT and was also effective when tested in two individuals with CPVT.


Top

Articles

Heterotypic interactions enabled by polarized neutrophil microdomains mediate thromboinflammatory injury pp384 - 391

Andrés Hidalgo, Jungshan Chang, Jung-Eun Jang, Anna J Peired, Elaine Y Chiang & Paul S Frenette

doi:10.1038/nm.1939

Signaling between endothelial and blood cell types controls inflammatory and thrombotic responses. Andrés Hidalgo and his coworkers now uncover a signaling mechanism by which the endothelium, acting on adherent leukocytes, promotes the capture of platelets or red blood cells by those leukocytes, contributing to pathology in mouse models of two very different types of disease—transfusion-related acute lung injury and sickle cell disease(pages 364–366).

See also: News and Views by Looney & Matthay


Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors pp392 - 400

Andrew R Reynolds, Ian R Hart, Alan R Watson, Jonathan C Welti, Rita G Silva, Stephen D Robinson, Georges Da Violante, Morgane Gourlaouen, Mishal Salih, Matt C Jones, Dylan T Jones, Garry Saunders, Vassiliki Kostourou, Françoise Perron-Sierra, Jim C Norman, Gordon C Tucker & Kairbaan M Hodivala-Dilke

doi:10.1038/nm.1941

Inhibitors of alphavbeta3 and alphavbeta5 integrins have previously been shown to inhibit tumor angiogenesis and growth and have entered human clinical trials. Andrew Reynolds and his coworkers now show that low (nanomolar) concentrations of these inhibitors can unexpectedly promote VEGF-dependent tumor angiogenesis and growth in vivo. Such effects could compromise the anticancer efficacy of these agents in humans.


Toll-like receptor 2–dependent induction of vitamin A–metabolizing enzymes in dendritic cells promotes T regulatory responses and inhibits autoimmunity pp401 - 409

Santhakumar Manicassamy, Rajesh Ravindran, Jiusheng Deng, Herold Oluoch, Timothy L Denning, Sudhir Pai Kasturi, Kristen M Rosenthal, Brian D Evavold & Bali Pulendran

doi:10.1038/nm.1925

Bali Pulendran and his colleagues explore ways that signaling through different pathogen receptors can program dendritic cells (DCs) to orchestrate inflammatory or tolerogenic immune responses. The yeast component zymosan triggers signaling through both Toll-like receptor 2 (TLR2) and the C-type lectin dectin-1. In the absence of TLR2, zymosan induces proinflammatory responses through dectin-1. But TLR2 triggering induces DCs to form the vitamin A–metabolizing enzyme Raldh2. The DCs can then form retinoic acid that acts in an autocrine manner on the DCs, programming them for the induction of regulatory T cell responses.


House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells pp410 - 416

Hamida Hammad, Marcello Chieppa, Frederic Perros, Monique A Willart, Ronald N Germain & Bart N Lambrecht

doi:10.1038/nm.1946

House dust mite allergen (HDM) is a potent trigger of airway inflammation. Dendritic cells (DCs) and lung epithelial cells both express the pathogen receptor TLR4, which senses lipopolysaccharide contaminating the allergen. Bart Lambrecht and his colleagues show that TLR4 on the epithelial cells, not the DCs, is the primary sensor of HDM. TLR4 on these lung structural cells is required for recruitment of DCs and the induction of allergic inflammation in response to HDM (pages 366–367).

See also: News and Views by Lloyd


Estrogen-dependent and C-C chemokine receptor-2–dependent pathways determine osteoclast behavior in osteoporosis pp417 - 424

Nikolaus B Binder, Birgit Niederreiter, Oskar Hoffmann, Richard Stange, Thomas Pap, Thomas M Stulnig, Matthias Mack, Reinhold G Erben, Josef S Smolen & Kurt Redlich

doi:10.1038/nm.1945

Kurt Redlich and his colleagues show that estrogen deficiency results in increased numbers of preosteoclast progenitor cells in the bones of mice. But they also find that lack of CCR2 in these future bone-resorbing cells prevents their maturation and thus protects the mice from osteoporosis, suggesting a future target for therapy in humans.


A new role of substance P as an injury-inducible messenger for mobilization of CD29+ stromal-like cells pp425 - 435

Hyun Sook Hong, Jungsun Lee, EunAh Lee, Young Sam Kwon, Eunkyung Lee, Woosung Ahn, Mei Hua Jiang, Jae Chan Kim & Youngsook Son

doi:10.1038/nm.1909

New factors in wound healing are sorely needed. Here Youngsook Son and colleagues identify substance P, a small neuropeptide, as one such factor that seems to work by mobilizing stromal-like cells to the site of wounding, accelerating the healing process (pages 367–369).

See also: News and Views by Robey


Top

Letters

Induction of natural killer T cell–dependent alloreactivity by administration of granulocyte colony–stimulating factor after bone marrow transplantation pp436 - 441

Edward S Morris, Kelli P A MacDonald, Rachel D Kuns, Helen M Morris, Tatjana Banovic, Alistair L J Don, Vanessa Rowe, Yana A Wilson, Neil C Raffelt, Christian R Engwerda, Angela C Burman, Kate A Markey, Dale I Godfrey, Mark J Smyth & Geoffrey R Hill

doi:10.1038/nm.1948

Granulocyte colony-stimulating factor (G-CSF) is used to accelerate neutrophil engraftment in bone marrow transplant (BMT) recipients to reduce bacterial infections but may also enhance the risk of graft-versus-host disease (GVHD). Morris et al. now show that total body irradiation increases the expression of the G-CSF receptor on recipient dendritic cells, resulting in the activation of donor natural killer T cells and enhanced GVHD when G-CSF is administered shortly after BMT (pages 363–364).

See also: News and Views by Martin


Deficiency of the intestinal enzyme acyl CoA:monoacylglycerol acyltransferase-2 protects mice from metabolic disorders induced by high-fat feeding pp442 - 446

Chi-Liang Eric Yen, Mei-Leng Cheong, Carrie Grueter, Ping Zhou, Junya Moriwaki, Jinny S Wong, Brian Hubbard, Stephen Marmor & Robert V Farese Jr

doi:10.1038/nm.1937

One way to reduce obesity is to alter fat absorption from the diet. Here Robert Farese, Jr. and his colleagues identify MGAT2 as a potential therapeutic target for doing so. The enzyme is mostly expressed in the gut of humans and mice, and its genetic deletion in mice results in slower kinetics of fat absorption—more of the fat is burned and less is stored, offering protection from diet-induced obesity.


Top

Technical Reports

Molecular therapy of obesity and diabetes by a physiological autoregulatory approach pp447 - 454

Lei Cao, En-Ju D Lin, Michael C Cahill, Chuansong Wang, Xianglan Liu & Matthew J During

doi:10.1038/nm.1933

Viral-mediated gene therapy presents many challenges in the clinic, including the potential for physiological effects that overshoot the intended goals. In a new report by Matthew During and his colleagues, the authors devise a scheme by which packaging of a microRNA into the virus, expressed under the control of a physiological response induced by the viral transgene, allows coordinated dampening of the transgene expression when the therapeutic response achieves a certain threshold.


Bioluminescence imaging of myeloperoxidase activity in vivo pp455 - 461

Shimon Gross, Seth T Gammon, Britney L Moss, Daniel Rauch, John Harding, Jay W Heinecke, Lee Ratner & David Piwnica-Worms

doi:10.1038/nm.1886

The leukocyte enzyme myeloperoxidase (MPO) is key to normal host defense mechanisms. Dysregulated MPO, however, is linked to acute and chronic inflammatory conditions, such as atherosclerosis and cancer. The authors describe a luminol-based bioluminescence imaging system that provides an optical readout of physiological levels of MPO activity in vivo. The system is demonstrated in animal models of acute dermatitis, focal arthritis and spontaneous large granular lymphocytic tumors.


Top

Corrigenda

Corrigendum: VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis p462

Betty YFY Tam, Kevin Wei, John S Rudge, Jana Hoffman, Joceyln Holash, Sang-ki Park, Jenny Yuan, Colleen Hefner, Cecile Chartier, Jeng-Shin Lee, Shelly Jiang, Nihar R Nayak, Frans A Kuypers, Lisa Ma, Uma Sundram, Grace Wu, Joseph A Garcia, Stanley L Schrier, Jacquelyn J Maher, Randall S Johnson, George D Yancopoulos, Richard C Mulligan & Calvin J Kuo

doi:10.1038/nm0409-462a


Corrigendum: Bone marrow stromal cells attenuate sepsis via prostaglandin E2–dependent reprogramming of host macrophages to increase their interleukin-10 production p462

Krisztián Németh, Asada Leelahavanichkul, Peter S T Yuen, Balázs Mayer, Alissa Parmelee, Kent Doi, Pamela G Robey, Kantima Leelahavanichkul, Beverly H Koller, Jared M Brown, Xuzhen Hu, Ivett Jelinek, Robert A Star & Éva Mezey

doi:10.1038/nm0409-462b


Corrigendum: The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases p462

Kevin J Whitehead, Aubrey C Chan, Sutip Navankasattusas, Wonshill Koh, Nyall R London, Jing Ling, Anne H Mayo, Stavros G Drakos, Christopher A Jones, Weiquan Zhu, Douglas A Marchuk, George E Davis & Dean Y Li

doi:10.1038/nm0409-462c


Corrigendum: Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. p462

Scott G Hansen, Cassandra Vieville, Nathan Whizin, Lia Coyne-Johnson, Don C Siess, Derek D Drummond, Alfred W Legasse, Michael K Axthelm, Kelli Oswald, Charles M Trubey, Michael Piatak Jr, Jeffrey D Lifson, Jay A Nelson, Michael A Jarvis & Louis J Picker

doi:10.1038/nm0409-462d


Top

Erratum

Erratum: Straight talk with...Mac Cowell and Jason Bobe p462

Prashant Nair

doi:10.1038/nm0409-462e


Top

Extra navigation

Subscribe to Nature Medicine

Subscribe

Open Innovation Challenges

naturejobs

ADVERTISEMENT